ZOLL® Medical Corporation, a company that manufactures medical devices and related software solutions has acquired Tel Aviv, Israel-based Kyma Medical Technologies, Ltd. for its wearable remote patient monitoring device for chronic cardiac illnesses. Under the terms of the agreement, ZOLL Medical Corporation will pay $35 million, plus milestone payments based on sales and the incorporation of Kyma technology into future products.
Wearable Cardiac Monitor Overview
Kyma’s μ-Cor is an innovative system for in-hospital or post-discharge monitoring of patients with chronic cardiac illnesses. The Kyma μ-Cor is designed to accurately measure fluid trends in the thoracic region and combined with the analysis performed at Kyma’s Service Center, providing healthcare professionals with accurate and reliable information to support timely decision-making. Specifically designed to facilitate patient compliance and improve data reliability, the wearable is easily attached to the patient’s torso and requires minimal patient involvement.
Patients wearing the device have reported the device is comfortable to wear and has been easily integrated into their daily routine. By facilitating early intervention by the physician prior to deterioration, the Kyma system helps support the goal of keeping patients out of the hospital and improving patient care.
Kyma is currently engaged in the development of additional sensors and algorithms to support management of heart failure, as well as a variety of other chronic diseases. ZOLL plans to maintain Kyma’s facilities and workforce in Israel and California as a part of ZOLL’s LifeVest division.
“The acquisition of Kyma Medical will allow ZOLL to broaden its product offerings with additional technologies designed to improve outcomes for heart failure patients with fluid management problems, with the goal of reducing hospitalizations,” said Jason T. Whiting, President of ZOLL LifeVest. “With the acquisition, Kyma’s technology will be able to better reach global markets through ZOLL’s existing network. Additionally, we expect to leverage Kyma’s strong R&D capabilities as well as the broader research talent available in Israel.”
